Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oryzanol + riboflavin + vitamin e is a combination therapy consisting of three small molecule nutritional supplements used primarily in China for the treatment of burning mouth syndrome (BMS). Oryzanol is a mixture of ferulic acid esters of sterols and triterpene alcohols that acts as an autonomic nervous system regulator. Riboflavin (vitamin B2) is a precursor to the essential coenzymes flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN), which are critical for energy metabolism and maintaining mucosal integrity. Vitamin E (alpha-tocopherol) serves as a potent lipid-soluble antioxidant, protecting cell membranes from oxidative damage. This triple-drug regimen, often referred to as Gu-Nucleus-E in Chinese clinical practice, is included in standard Chinese pharmacotherapy textbooks for oral mucosal diseases, although its efficacy is sometimes characterized as unstable with a tendency for symptom recurrence upon withdrawal.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oryzanol + riboflavin + vitamin e.